Media coverage about Edwards Lifesciences (NYSE:EW) has been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edwards Lifesciences earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.9623641098042 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Robert W.A. Sellers Sells 12,020 Shares of Edwards Lifesciences Corp (EW) Stock (americanbankingnews.com)
- William Blair Weighs in on Edwards Lifesciences Corp’s Q2 2018 Earnings (EW) (americanbankingnews.com)
- Leerink Swann Weighs in on Edwards Lifesciences Corp’s Q1 2018 Earnings (EW) (americanbankingnews.com)
- Q1 2018 Earnings Forecast for Edwards Lifesciences Corp (EW) Issued By Jefferies Group (americanbankingnews.com)
- Edwards Lifesciences Corp (EW) Expected to Post FY2017 Earnings of $3.77 Per Share (americanbankingnews.com)
Several analysts recently commented on EW shares. SunTrust Banks reaffirmed a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences in a report on Wednesday, January 31st. Cowen set a $135.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a report on Sunday, December 10th. BMO Capital Markets reissued a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a report on Friday, December 8th. Canaccord Genuity reissued a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, November 29th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $155.00 price objective on shares of Edwards Lifesciences in a report on Friday, February 2nd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $139.25.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. The firm had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The business’s revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share. research analysts predict that Edwards Lifesciences will post 4.49 EPS for the current fiscal year.
Edwards Lifesciences announced that its Board of Directors has initiated a share buyback program on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its stock is undervalued.
In related news, VP Robert W.A. Sellers sold 12,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $131.03, for a total transaction of $1,574,980.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $127.24, for a total value of $674,372.00. Following the transaction, the vice president now owns 24,908 shares in the company, valued at approximately $3,169,293.92. The disclosure for this sale can be found here. Insiders sold 175,940 shares of company stock worth $20,049,578 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.